KGKatherine Y. Gross

Katherine Y. Gross

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Katherine Y. Gross has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Precision RNAi for fibrodysplasia ossificans progressiva in mice using a combinatorial unimolecular allele selective approach

    by Yeon-Suk Yang, Katherine Y. Gross, David Cooper, Sachin Chaugule, Mi-Jeong Kim, Christopher Dahlke, Emma Mayer, Eric M. Kercher, Ji Woong Kim, Thomas Ormsby, et al.

  • Open Access

    One Scaffold, Many Targets: Fully Modified RNA Nanostructures for Multi-Gene Silencing Beyond the Liver

    by Hassan H. Fakih, Ashley Summers, Qi Tang, Rosemary Gagnon, Brianna Bramato, Raymond Furgal, Katherine Y. Gross, Jana H. Fakih, Dimas Echeverria, Hanadi Sleiman, et al.

    Therapeutic siRNAs are a major clinical modality for hepatic gene silencing, but efficient extrahepatic delivery and multi-gene modulation remain significant barriers. Nucleic acid nanotechnology offers programmable assembly, but conventional structures suffer from enzymatic instability in vivo . Here we report fully chemically modified RNA nanostructures (FMRNs)—a vehicle-free platform entirely composed of stabilized therapeutic nucleic acids that integrate structural precision with metabolic durability. Following systemic administration, FMRNs exhibit enhanced pharmacokinetics and extrahepatic accumulation, with in vivo behavior influenced greatly by hydrodynamic size rather than molecular weight. Using triangular and square geometries, we demonstrate programmable control over siRNA stoichiometry to achieve sustained, simultaneous silencing of up to four genes from a single entity. Nanostructure assembly alone drives productive delivery, especially to heart and muscle, matching lipophilic conjugation. Furthermore, cerebrospinal fluid administration reveals that larger FMRNs improve central nervous system distribution and retention revealing physicochemical parameters that impact brain exposure. FMRNs establish a modular and effective platform combining improved pharmacokinetics, extrahepatic delivery, and multi-gene silencing for complex diseases.

  • RNAi-mediated p38δ silencing mitigates anthracycline cardiotoxicity in female mice

    by Katy A. Trampel, Katherine Y. Gross, Daniel O'REilly, Altynai Melisova, Batool Salman, Sophie Green, Sharon A. George, Anastasia Khvorova, Igor R. Efimov, Tatiana Efimova

    This study presents the first isoform-specific inhibition of p38δ using a docosanoic (DCA)-conjugated, fully chemically stabilized siRNA. Our lead compound, si644, achieves potent, durable, and well-tolerated p38δ silencing in vivo in mouse hearts and ex vivo in human cardiac organotypic slices. si644-mediated p38δ silencing protects female mice from DIC by mitigating DOX-induced structural, electrophysiological, fibrotic, and inflammatory remodeling. These findings establish p38δ inhibition as a promising therapeutic strategy for preventing anthracycline cardiotoxicity.


  • Open Access

    Intradermal delivery of lipophilic siRNAs enables prolonged skin retention and sustained gene silencing in a porcine model

    by Hassan H. Fakih, Mohammad Zain Ui Abideen, Mohamad Omar Rachid, Katherine Y. Gross, Thomas J. R. Ormsby, Vella M. Ross, Rosemary Gagnon, Christopher Dahlke, Raymond C. Furgal, Clemens Lochmann, et al.

    Small interfering RNAs (siRNAs) offer significant therapeutic potential; however, extrahepatic applications, particularly to the skin, remain a challenge. Limited work has explored siRNA therapies for the skin, the largest organ in the human body, where dermatological conditions affect over one-third of the population worldwide. The skin’s external location makes it easily accessible for direct, local administration. Here, we present the in vivo intradermal delivery of therapeutic siRNAs into a porcine model whose skin structure most closely resembles that of human skin, demonstrating functional, and sustained gene silencing. We characterize two siRNA conjugates in human ex vivo and porcine in vivo skin models, showing that increased hydrophobicity significantly enhances skin retention and efficacy of siRNAs. Using a validated JAK1-targeting compound, we demonstrate that local delivery of siRNA enables accumulation across multiple cell types and suppression of JAK1-dependent inflammatory pathway in human skin ex vivo. In porcine models, intradermal injections result in prolonged skin siRNA retention for more than eight weeks, limited systemic tissue exposure, and sustained gene silencing for at least one month. These results underscore the importance of tailored siRNA conjugate design for achieving optimal skin biodistribution and therapeutic efficacy, providing a foundation for siRNA-based treatments for a broad range of dermatological conditions.


  • Open Access

    Potent and durable gene modulation in heart and muscle with chemically defined siRNAs

    by Hassan H. Fakih, Clemens Lochmann, Rosemary Gagnon, Ashley Summers, Jillian Caiazzi, Julianna E. Buchwald, Qi Tang, Bruktawit Maru, Samuel R. Hildebrand, Mohammad Zain Ui Abideen, et al.

    Small interfering RNA (siRNAs) hold immense promise for treating cardiac and muscular diseases, but robust and scalable delivery to these tissues remains a challenge. Recent advances in delivery strategies to muscle include conjugation of biologics (antibody/antibody fragments, peptides), which are currently in clinical development. However, the manufacturing of biologic-siRNA conjugates is a challenging and complex process. By contrast, lipophilic siRNAs are readily chemically synthesized at scale and support sufficient cardiac and skeletal muscle delivery. In this work, we refine siRNA design elements to enhance potency and durability and support clinically relevant silencing in muscle. Applying this strategy for siRNAs targeting myostatin ( MSTN ), a key target in muscle-wasting conditions, we show that a single subcutaneous dose in mice achieved robust and durable silencing (∼80% inhibition up to 6 weeks, ∼30% at 14 weeks). Biweekly dosing resulted in >95% reduction of circulating MSTN for half a year, with no observed systemic or target-related toxicity. MSTN inhibition resulted in muscle growth and increased lean muscle mass, correlating with improved grip strength. Interestingly, the functional impact on muscle growth and strength significantly outlasts the target silencing, suggesting extended pharmacological effects. Systemic administration was equally efficacious in all muscle groups tested, including skeletal muscle, heart, tongue and diaphragm. The informational nature of the muscle-active chemically defined siRNA scaffold was confirmed by demonstrating muscle and heart efficacy with three additional targets. Our findings pave the way for potent and long-lasting gene modulation in muscle using chemically defined, lipophilic siRNAs, offering a new avenue for treating muscular diseases.